New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:01 EDTHA, BOBE, ALGT, APC, TIF, NTI, KIRK, HEES, BIIB, ED, SBLK, NM, IPHI, COG, AXLL, TEVA, YUM, NS, MTRNOn The Fly: Analyst Upgrade Summary
Allegiant Travel (ALGT) upgraded to Outperform from Market Perform at Raymond James... Axiall (AXLL) upgraded to Buy from Neutral at Goldman... Biogen (BIIB) upgraded to Outperform from Market Perform at BMO Capital... Bob Evans (BOBE) upgraded to Buy from Hold at Miller Tabak... Cabot Oil & Gas (COG) upgraded to Buy from Neutral at UBS... H&E Equipment (HEES) upgraded to Buy from Neutral at UBS... Hawaiian Holdings (HA) upgraded to Buy from Hold at Deutsche Bank... Inphi (IPHI) upgraded to Buy from Hold at Jefferies... Kirkland's (KIRK) upgraded to Buy from Hold at KeyBanc... Materion (MTRN) upgraded to Buy from Hold at KeyBanc... Navios Maritime (NM) upgraded to Buy from Hold at Stifel... Northern Tier (NTI) upgraded to Overweight from Equal Weight at Barclays... NuStar Energy (NS) upgraded to Overweight from Neutral at JPMorgan... Star Bulk Carriers (SBLK) upgraded to Buy from Hold at Stifel... Tiffany (TIF) upgraded to Buy from Neutral at Citigroup... Yum! Brands (YUM) upgraded to Outperform from Neutral at RW Baird... Consolidated Edison (ED) upgraded to Buy from Hold at Argus... Anadarko (APC) upgraded to Buy from Hold at Argus... Teva (TEVA) upgraded to Outperform from Market Perform at Leerink.
News For ALGT;AXLL;BIIB;BOBE;COG;HEES;HA;IPHI;KIRK;MTRN;NM;NTI;NS;SBLK;TIF;YUM;ED;APC;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
March 18, 2015
11:36 EDTTEVAIgnyta price target raised to $17 from $14 at Leerink
Subscribe for More Information
10:08 EDTTEVAEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.
08:49 EDTAPCAnadarko purchases 20% interest in Saddlehorn Pipeline
Subscribe for More Information
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
07:29 EDTIPHINorthland Capital Markets to hold a conference
Subscribe for More Information
07:21 EDTAPC, COGE&P stocks should be bought on weakness, says Stifel
Subscribe for More Information
07:13 EDTTEVATeva volatility elevated, shares near four year high
Subscribe for More Information
07:08 EDTIPHIInphi weakness creates buying opportunity, says Stifel
Subscribe for More Information
March 17, 2015
19:42 EDTTEVAOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTTEVAIgnyta acquires 4 oncology R&D assets from Teva for 1.5M shares of common stock
Teva (TEVA) and Ignyta (RXDX) announced the acquisition by Ignyta of the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Concurrently, Ignyta has entered into stock purchase agreements with Teva, and selected additional healthcare investors, whereby Teva will purchase a further 1.5 million shares of common Ignyta stock at a price of $10 per share in a registered direct offering. The other investors will purchase an additional 2.7M shares at $10 per share, valuing the total offering at approximately $41.6M. Under the terms of the asset purchase agreement with Teva, Ignyta is acquiring all of Teva’s assets and worldwide rights relating to four oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Teva has agreed not to sell or otherwise transfer any of these shares until March 17, 2016, and Ignyta is required to register the resale of these shares with the SEC prior to such date. Ignyta also assumed all of Teva’s ongoing obligations under certain contracts relating to the purchased programs, including the agreements under which Teva in-licensed rights to the assets.
10:26 EDTTEVAOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTCOGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:10 EDTCOGCabot Oil & Gas upgraded to Buy from Accumulate at Global Hunter
Subscribe for More Information
March 16, 2015
14:10 EDTTIFTiffany March volatility elevated into Q3 and outlook
Tiffany March call option implied volatility is at 67, April is at 31, May is at 26, August is at 25; compared to its 26-week average of 26 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on March 20.
11:40 EDTTEVAEnzo Biochem to request rehearing of court of appeals decision
Enzo Biochem (ENZ) said, acting upon advice of counsel, that it disagrees with the March 16 split 2-to-1 decision of the Court of Appeals sitting in panel for the Federal Circuit that reverses-in-part and vacates-in-part the judgment in Enzo’s favor that Applera Corp., now Life Technologies (LIFE), infringed Enzo’s patents covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code, and remands the case to the District Court as to whether the accused product infringes. Counter to the District Court’s construction of the ‘767 patent as allowing for directly-detectable labels on nucleotides and polynucleotides, and counter to the jury’s verdict that the patent describes such labelling, the Court of Appeals, held such labelling excluded by claim 1 of that patent. Enzo notes also that the Court’s partial vacatur and reversal of the judgment does not end the case, but remands the case back to the District Court to find whether the accused product infringes. Enzo will request rehearing of that decision, both by the original panel and by the full en banc Court. Enzo believes rehearing is warranted by the panel’s failure to give appropriate weight to fact findings, including facts found by the jury, consistent with a broader construction of the patent, as required by the Supreme Court’s recent decision in Teva Pharmaceuticals (TEVA).
10:28 EDTTEVAOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
10:02 EDTALGTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTALGTAllegiant Travel downgraded to Market Perform at Raymond James
As previously reported, Raymond James downgraded Allegiant Travel to Market Perform from Outperform due to low upside potential. The firm does not recommend selling the stock, as domestic demand remains healthy and further upside to estimates exists if fuel prices remain lower for longer than forecast.
08:44 EDTTEVAFDA warning on liquid bendamustine may help Eagle's EP-3102, says Piper Jaffray
Subscribe for More Information
07:09 EDTALGTAllegiant Travel downgraded to Market Perform from Outperform at Raymond James
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use